Harmony Biosciences Holdings, Inc.
HRMY
$28.46
$0.521.86%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 714.73M | 681.88M | 656.11M | 617.51M | 582.02M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 714.73M | 681.88M | 656.11M | 617.51M | 582.02M |
| Cost of Revenue | 156.82M | 145.56M | 135.08M | 127.94M | 121.24M |
| Gross Profit | 557.92M | 536.32M | 521.03M | 489.57M | 460.79M |
| SG&A Expenses | 221.27M | 219.56M | 209.36M | 200.97M | 192.69M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 523.91M | 506.58M | 478.02M | 413.87M | 389.99M |
| Operating Income | 190.83M | 175.30M | 178.09M | 203.64M | 192.03M |
| Income Before Tax | 191.80M | 175.34M | 165.00M | 187.40M | 173.40M |
| Income Tax Expenses | 46.31M | 52.71M | 50.01M | 49.70M | 44.54M |
| Earnings from Continuing Operations | 145.49 | 122.63 | 114.99 | 137.70 | 128.85 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 145.49M | 122.63M | 114.99M | 137.70M | 128.85M |
| EBIT | 190.83M | 175.30M | 178.09M | 203.64M | 192.03M |
| EBITDA | 214.94M | 199.56M | 202.50M | 228.06M | 216.39M |
| EPS Basic | 2.56 | 2.15 | 1.98 | 2.35 | 2.16 |
| Normalized Basic EPS | 2.11 | 1.92 | 1.88 | 2.10 | 1.92 |
| EPS Diluted | 2.51 | 2.11 | 1.95 | 2.31 | 2.12 |
| Normalized Diluted EPS | 2.07 | 1.89 | 1.85 | 2.07 | 1.90 |
| Average Basic Shares Outstanding | 227.54M | 228.76M | 231.76M | 234.93M | 237.89M |
| Average Diluted Shares Outstanding | 231.46M | 232.10M | 234.67M | 237.88M | 241.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |